Prostate Cancer Drugs - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509249991

Publication Date:

September 11, 2024

Pages:

164

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Prostate Cancer Drugs was estimated to be worth US$ 6310.3 million in 2023 and is forecast to a readjusted size of US$ 10100 million by 2030 with a CAGR of 6.5% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Prostate Cancer Drugs by region & country, by Type, and by Application.
The Prostate Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (K MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Drugs.
麻豆原创 Segmentation
By Company
AbbVie
Astellas Pharma
Astra Zeneca
Johnson & Johnson
Sanofi
GlaxoSmithKline
Merck Group
Novartis
Amgen
Bayer HealthCare
Ferring Pharmaceutical
Janssen Pharmaceuticals
Endo Pharmaceuticals
BMS
Takeda Pharmaceuticals
Northwest Biotherapeutics
Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals
Segment by Type:
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Segment by Application
Clinics
Hospitals
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Prostate Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Prostate Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Prostate Cancer Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Prostate Cancer Drugs Product Introduction
1.2 Global Prostate Cancer Drugs 麻豆原创 Size Forecast
1.2.1 Global Prostate Cancer Drugs Sales Value (2019-2030)
1.2.2 Global Prostate Cancer Drugs Sales Volume (2019-2030)
1.2.3 Global Prostate Cancer Drugs Sales Price (2019-2030)
1.3 Prostate Cancer Drugs 麻豆原创 Trends & Drivers
1.3.1 Prostate Cancer Drugs Industry Trends
1.3.2 Prostate Cancer Drugs 麻豆原创 Drivers & Opportunity
1.3.3 Prostate Cancer Drugs 麻豆原创 Challenges
1.3.4 Prostate Cancer Drugs 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Prostate Cancer Drugs Players Revenue Ranking (2023)
2.2 Global Prostate Cancer Drugs Revenue by Company (2019-2024)
2.3 Global Prostate Cancer Drugs Players Sales Volume Ranking (2023)
2.4 Global Prostate Cancer Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Prostate Cancer Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Prostate Cancer Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Prostate Cancer Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Prostate Cancer Drugs
2.9 Prostate Cancer Drugs 麻豆原创 Competitive Analysis
2.9.1 Prostate Cancer Drugs 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Prostate Cancer Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Hormonal Therapy
3.1.2 Chemotherapy
3.1.3 Immunotherapy
3.1.4 Targeted Therapy
3.2 Global Prostate Cancer Drugs Sales Value by Type
3.2.1 Global Prostate Cancer Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Prostate Cancer Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Prostate Cancer Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Prostate Cancer Drugs Sales Volume by Type
3.3.1 Global Prostate Cancer Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Prostate Cancer Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Prostate Cancer Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Prostate Cancer Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinics
4.1.2 Hospitals
4.1.3 Others
4.2 Global Prostate Cancer Drugs Sales Value by Application
4.2.1 Global Prostate Cancer Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Prostate Cancer Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Prostate Cancer Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Prostate Cancer Drugs Sales Volume by Application
4.3.1 Global Prostate Cancer Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Prostate Cancer Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Prostate Cancer Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Prostate Cancer Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Prostate Cancer Drugs Sales Value by Region
5.1.1 Global Prostate Cancer Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Prostate Cancer Drugs Sales Value by Region (2019-2024)
5.1.3 Global Prostate Cancer Drugs Sales Value by Region (2025-2030)
5.1.4 Global Prostate Cancer Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Prostate Cancer Drugs Sales Volume by Region
5.2.1 Global Prostate Cancer Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Prostate Cancer Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Prostate Cancer Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Prostate Cancer Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Prostate Cancer Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Prostate Cancer Drugs Sales Value, 2019-2030
5.4.2 North America Prostate Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Prostate Cancer Drugs Sales Value, 2019-2030
5.5.2 Europe Prostate Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Prostate Cancer Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Prostate Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Prostate Cancer Drugs Sales Value, 2019-2030
5.7.2 South America Prostate Cancer Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Prostate Cancer Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Prostate Cancer Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Prostate Cancer Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Prostate Cancer Drugs Sales Value
6.2.1 Key Countries/Regions Prostate Cancer Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Prostate Cancer Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Prostate Cancer Drugs Sales Value, 2019-2030
6.3.2 United States Prostate Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Prostate Cancer Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Prostate Cancer Drugs Sales Value, 2019-2030
6.4.2 Europe Prostate Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Prostate Cancer Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Prostate Cancer Drugs Sales Value, 2019-2030
6.5.2 China Prostate Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Prostate Cancer Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Prostate Cancer Drugs Sales Value, 2019-2030
6.6.2 Japan Prostate Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Prostate Cancer Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Prostate Cancer Drugs Sales Value, 2019-2030
6.7.2 South Korea Prostate Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Prostate Cancer Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Prostate Cancer Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Prostate Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Prostate Cancer Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Prostate Cancer Drugs Sales Value, 2019-2030
6.9.2 India Prostate Cancer Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Prostate Cancer Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AbbVie
7.1.1 AbbVie Company Information
7.1.2 AbbVie Introduction and Business Overview
7.1.3 AbbVie Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 AbbVie Prostate Cancer Drugs Product Offerings
7.1.5 AbbVie Recent Development
7.2 Astellas Pharma
7.2.1 Astellas Pharma Company Information
7.2.2 Astellas Pharma Introduction and Business Overview
7.2.3 Astellas Pharma Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Astellas Pharma Prostate Cancer Drugs Product Offerings
7.2.5 Astellas Pharma Recent Development
7.3 Astra Zeneca
7.3.1 Astra Zeneca Company Information
7.3.2 Astra Zeneca Introduction and Business Overview
7.3.3 Astra Zeneca Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Astra Zeneca Prostate Cancer Drugs Product Offerings
7.3.5 Astra Zeneca Recent Development
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Information
7.4.2 Johnson & Johnson Introduction and Business Overview
7.4.3 Johnson & Johnson Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Johnson & Johnson Prostate Cancer Drugs Product Offerings
7.4.5 Johnson & Johnson Recent Development
7.5 Sanofi
7.5.1 Sanofi Company Information
7.5.2 Sanofi Introduction and Business Overview
7.5.3 Sanofi Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Sanofi Prostate Cancer Drugs Product Offerings
7.5.5 Sanofi Recent Development
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Company Information
7.6.2 GlaxoSmithKline Introduction and Business Overview
7.6.3 GlaxoSmithKline Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 GlaxoSmithKline Prostate Cancer Drugs Product Offerings
7.6.5 GlaxoSmithKline Recent Development
7.7 Merck Group
7.7.1 Merck Group Company Information
7.7.2 Merck Group Introduction and Business Overview
7.7.3 Merck Group Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Merck Group Prostate Cancer Drugs Product Offerings
7.7.5 Merck Group Recent Development
7.8 Novartis
7.8.1 Novartis Company Information
7.8.2 Novartis Introduction and Business Overview
7.8.3 Novartis Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Novartis Prostate Cancer Drugs Product Offerings
7.8.5 Novartis Recent Development
7.9 Amgen
7.9.1 Amgen Company Information
7.9.2 Amgen Introduction and Business Overview
7.9.3 Amgen Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Amgen Prostate Cancer Drugs Product Offerings
7.9.5 Amgen Recent Development
7.10 Bayer HealthCare
7.10.1 Bayer HealthCare Company Information
7.10.2 Bayer HealthCare Introduction and Business Overview
7.10.3 Bayer HealthCare Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Bayer HealthCare Prostate Cancer Drugs Product Offerings
7.10.5 Bayer HealthCare Recent Development
7.11 Ferring Pharmaceutical
7.11.1 Ferring Pharmaceutical Company Information
7.11.2 Ferring Pharmaceutical Introduction and Business Overview
7.11.3 Ferring Pharmaceutical Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Ferring Pharmaceutical Prostate Cancer Drugs Product Offerings
7.11.5 Ferring Pharmaceutical Recent Development
7.12 Janssen Pharmaceuticals
7.12.1 Janssen Pharmaceuticals Company Information
7.12.2 Janssen Pharmaceuticals Introduction and Business Overview
7.12.3 Janssen Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Janssen Pharmaceuticals Prostate Cancer Drugs Product Offerings
7.12.5 Janssen Pharmaceuticals Recent Development
7.13 Endo Pharmaceuticals
7.13.1 Endo Pharmaceuticals Company Information
7.13.2 Endo Pharmaceuticals Introduction and Business Overview
7.13.3 Endo Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Endo Pharmaceuticals Prostate Cancer Drugs Product Offerings
7.13.5 Endo Pharmaceuticals Recent Development
7.14 BMS
7.14.1 BMS Company Information
7.14.2 BMS Introduction and Business Overview
7.14.3 BMS Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.14.4 BMS Prostate Cancer Drugs Product Offerings
7.14.5 BMS Recent Development
7.15 Takeda Pharmaceuticals
7.15.1 Takeda Pharmaceuticals Company Information
7.15.2 Takeda Pharmaceuticals Introduction and Business Overview
7.15.3 Takeda Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Takeda Pharmaceuticals Prostate Cancer Drugs Product Offerings
7.15.5 Takeda Pharmaceuticals Recent Development
7.16 Northwest Biotherapeutics
7.16.1 Northwest Biotherapeutics Company Information
7.16.2 Northwest Biotherapeutics Introduction and Business Overview
7.16.3 Northwest Biotherapeutics Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Northwest Biotherapeutics Prostate Cancer Drugs Product Offerings
7.16.5 Northwest Biotherapeutics Recent Development
7.17 Teva Pharmaceutical
7.17.1 Teva Pharmaceutical Company Information
7.17.2 Teva Pharmaceutical Introduction and Business Overview
7.17.3 Teva Pharmaceutical Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Teva Pharmaceutical Prostate Cancer Drugs Product Offerings
7.17.5 Teva Pharmaceutical Recent Development
7.18 Boehringer Ingelheim
7.18.1 Boehringer Ingelheim Company Information
7.18.2 Boehringer Ingelheim Introduction and Business Overview
7.18.3 Boehringer Ingelheim Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Boehringer Ingelheim Prostate Cancer Drugs Product Offerings
7.18.5 Boehringer Ingelheim Recent Development
7.19 Foresee Pharmaceuticals
7.19.1 Foresee Pharmaceuticals Company Information
7.19.2 Foresee Pharmaceuticals Introduction and Business Overview
7.19.3 Foresee Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Foresee Pharmaceuticals Prostate Cancer Drugs Product Offerings
7.19.5 Foresee Pharmaceuticals Recent Development
7.20 Tokai Pharmaceuticals
7.20.1 Tokai Pharmaceuticals Company Information
7.20.2 Tokai Pharmaceuticals Introduction and Business Overview
7.20.3 Tokai Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Tokai Pharmaceuticals Prostate Cancer Drugs Product Offerings
7.20.5 Tokai Pharmaceuticals Recent Development
7.21 Spectrum Pharmaceuticals
7.21.1 Spectrum Pharmaceuticals Company Information
7.21.2 Spectrum Pharmaceuticals Introduction and Business Overview
7.21.3 Spectrum Pharmaceuticals Prostate Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
7.21.4 Spectrum Pharmaceuticals Prostate Cancer Drugs Product Offerings
7.21.5 Spectrum Pharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Prostate Cancer Drugs Industrial Chain
8.2 Prostate Cancer Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Prostate Cancer Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Prostate Cancer Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

AbbVie
Astellas Pharma
Astra Zeneca
Johnson & Johnson
Sanofi
GlaxoSmithKline
Merck Group
Novartis
Amgen
Bayer HealthCare
Ferring Pharmaceutical
Janssen Pharmaceuticals
Endo Pharmaceuticals
BMS
Takeda Pharmaceuticals
Northwest Biotherapeutics
Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.